Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.62 (market cap $31.07B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $62.94 (market cap $78.49B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 2.5× GE HealthCare Technologies Inc. Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.38%). Which is the better fit depends on your goals.
| GEHC | MDLZ | |
|---|---|---|
Market Cap | $31.07B | $78.49B |
Volume | 3,443,020 | 7,021,971 |
Sector | Health | Consumer Staples |
52-Week High | $88.16 | $64.99 |
52-Week Low | $59.48 | $51.51 |
Enterprise Value | $39.53B | $98.84B |
Dividend Yield | 0.23% | 3.38% |
Typical Hold Time | — | 108 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Mondelez International (MDLZ) trades at $62.57, up 1.26% with strong technical momentum and bullish moving averages. The company has beaten earnings expectations for three consecutive quarters, with Q3 2026 results pending. Revenue growth continues with $38.54B in 2025, though net margins compressed to 6.36% from previous highs. Analyst consensus remains strongly bullish with a $70.29 price target, supported by recent dividend increases and strategic expansions.
MDLZ offers stable growth with defensive characteristics amid market volatility. Key opportunities include margin recovery from productivity gains and emerging market expansion. Risks include persistent cocoa cost pressures and competitive snack category dynamics. The stock presents a compelling risk-reward profile for long-term investors seeking quality consumer staples exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
